Efficacy and Safety of TLL-018 in Moderate to Severe Chronic Spontaneous Urticaria Patients with Inadequate Response to H1 Antihistamine: Results from a Phase b Study

被引：0
|
作者：
Lu, Qianjin [1 ]
Yang, Bin [2 ]
Liu, Lunfei [3 ]
Li, Linfeng [4 ]
Liu, Weijun [5 ]
Yao, Xu [1 ]
Man, Xiaoyong [6 ]
Chen, Aijun [7 ]
Shi, Yuling [8 ]
Ding, Yangfeng [8 ]
Sun, Qing [9 ]
Tao, Juan [10 ]
Liang, Chris [11 ]
Liu, Yong [11 ]
Liu, Donghua [11 ]
Sun, Peiyu [11 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Dermatol, Beijing, Peoples R China
[2] Southern Med Univ, Dermatol Hosp, Guangzhou, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 4, Hangzhou, Peoples R China
[4] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China
[5] Dermatol Hosp Jiangxi Prov, Nanchang, Jiangxi, Peoples R China
[6] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[7] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[8] Tongji Univ, Sch Med, Shanghai Skin Dis Hosp, Shanghai, Peoples R China
[9] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[10] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[11] Hangzhou Highlightll Pharmaceut Co Ltd, Hangzhou, Peoples R China
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
L36
引用
收藏
页码：AB372 / AB372
页数：1
相关论文
共 50 条
  • [21] Comparably high Exposure to chronic spontaneous Urticaria in Patients with moderate and severe Disease Activity: Results from the ASSURE-csU Study
    Marsland, Alexander
    Abuzakouk, Mohamed
    Balp, Maria Magdalena
    Berard, Frederic
    Canonica, Giorgio Walter
    Gimenez-Arnau, Ana
    Grattan, Clive
    Hollis, Kelly
    Hunter, Shannon
    Khalil, Sam
    Knulst, Andre C.
    Lacour, Jean-Phillipe
    Lynde, Charles
    McBride, Doreen
    Nakonechna, Alla
    Ortiz De Frutoz, Francisco J.
    Elberink, J. N. G. Oude
    Sussman, Gordon
    Weller, Karsten
    Maurer, Marcus
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 9 - 10
  • [22] Efficacy and safety of efalizumab in patients with chronic moderate to severe plaque psoriasis: Results from a postapproval phase IIIb/IV study (control II)
    Lotti, Torello
    Licu, Daiana
    Chimenti, Sergio
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB179 - AB179
  • [23] Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
    Asahina, Akihiko
    Nakagawa, Hidemi
    Etoh, Takafumi
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2010, 37 (04): : 299 - 310
  • [24] Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial
    Atsushi Fukunaga
    Yoshiko Oda
    Ken Washio
    Takashi Omori
    Yasumasa Kakei
    Michihiro Hide
    Chikako Nishigori
    Trials, 21
  • [25] Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial
    Fukunaga, Atsushi
    Oda, Yoshiko
    Washio, Ken
    Omori, Takashi
    Kakei, Yasumasa
    Hide, Michihiro
    Nishigori, Chikako
    TRIALS, 2020, 21 (01)
  • [26] A randomized placebo-controlled double-blind pilot study of methotrexate in the treatment of H1 antihistamine-resistant chronic spontaneous urticaria
    Sharma, Vinod K.
    Singh, Saurabh
    Ramam, M.
    Kumawat, Mahesh
    Kumar, Rakesh
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2014, 80 (02): : 122 - 128
  • [27] Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study
    Fukunaga, Atsushi
    Kakei, Yasumasa
    Murakami, Sae
    Kan, Yuji
    Masuda, Koji
    Jinnin, Masatoshi
    Washio, Ken
    Amano, Hiroo
    Nagano, Tohru
    Yamamoto, Akihisa
    Otsuka, Toshihiro
    Takahagi, Shunsuke
    Takenaka, Motoi
    Ishiguro, Naoko
    Hayama, Koremasa
    Inomata, Naoko
    Nakagawa, Yukinobu
    Sugiyama, Akiko
    Hide, Michihiro
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [28] Angioedema and angioedema management from ASTERIA II: a phase III, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 antihistamine treatment
    Zazzali, J. L.
    Rosen, K. E.
    Hsieh, H-J
    ALLERGY, 2013, 68 : 43 - 43
  • [29] Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial
    Staubach, P.
    Metz, M.
    Chapman-Rothe, N.
    Sieder, C.
    Braeutigam, M.
    Canvin, J.
    Maurer, M.
    ALLERGY, 2016, 71 (08) : 1135 - 1144
  • [30] Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: Primary results of a placebo- and active-controlled phase 2b dose finding study
    Maurer, M.
    Gimenez-Arnau, A.
    Sussman, G.
    Loeffler, J.
    Barve, A.
    Severin, T.
    Janocha, R.
    ALLERGY, 2018, 73 : 837 - 837
12345